Amneal Pharmaceuticals (NASDAQ:AMRX) Downgraded by Zacks Research to “Hold”

Zacks Research lowered shares of Amneal Pharmaceuticals (NASDAQ:AMRX) from a strong-buy rating to a hold rating in a research note issued to investors on Monday,Zacks reports.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. UBS Group lifted their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $22.00 target price on shares of Amneal Pharmaceuticals in a research note on Wednesday, August 26th. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 26th. Finally, Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Amneal Pharmaceuticals Trading Down 2.2%

Shares of Amneal Pharmaceuticals stock opened at $17.05 on Monday. The company has a 50-day moving average of $17.76 and a two-hundred day moving average of $15.00. Amneal Pharmaceuticals has a 12-month low of $9.49 and a 12-month high of $19.26. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65. The stock has a market cap of $5.44 billion, a PE ratio of 34.80 and a beta of 1.24.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.The business had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, research analysts anticipate that Amneal Pharmaceuticals will post 0.94 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, EVP Jason Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the sale, the executive vice president owned 35,171 shares in the company, valued at $611,975.40. The trade was a 85.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Nikita Shah sold 146,403 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the transaction, the executive vice president directly owned 253,390 shares of the company’s stock, valued at approximately $4,436,858.90. This represents a 36.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 413,016 shares of company stock valued at $7,216,567. Insiders own 17.30% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Amneal Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock worth $793,000 after buying an additional 4,178 shares during the period. Millennium Management LLC increased its stake in Amneal Pharmaceuticals by 32.6% during the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock worth $17,492,000 after acquiring an additional 512,842 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Amneal Pharmaceuticals during the first quarter worth about $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Amneal Pharmaceuticals by 5.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock worth $2,807,000 after purchasing an additional 16,536 shares during the period. Finally, Creative Planning raised its holdings in shares of Amneal Pharmaceuticals by 61.9% in the 2nd quarter. Creative Planning now owns 23,896 shares of the company’s stock worth $193,000 after purchasing an additional 9,136 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.